Skip to main content

Table 2 Estimated OR/WMD and 95% CI from pairwise meta-analysis in terms of Blood loss, Transfusion risk, Change of Hb, DVT and PE

From: Hemostatic effect of tourniquet combined with tranexamic acid in total knee arthroplasty: a network meta-analysis

Included studies

Comparisons

Pairwise meta-analysis

WMD(95%CI)

I2

Ph

The total blood loss

(PMID:29544472;PMID:29257010;PMID:27267228;PMID:27194493;PMID:26507526;PMID:27259391;PMID:27222617;PMID:26894222;PMID:12697586;PMID:11476309;PMID:10673876; PMID:8636182)

1 study

IV vs. control

−277.34 (−431.85–122.83)

NA

NA

1 study

Topical vs. control

−307.78 (−460.92–154.64)

NA

NA

1 study

Topical vs. IV

−30.44 (−163.81–102.93)

NA

NA

2 studies

IV + topical vs. IV

−218.13 (−282.59–153.68)

46.8%

0.17

1 study

Oral vs. topical

−83.60 (−203.84–36.64)

NA

NA

1 study

T VS. IV + topical

956.60 (829.31–1083.89)

NA

NA

6 studies

IV + T vs. T

−156.09 (−179.41–132.78)

98.1%

<0.01

2 studies

Topical+T vs. T

−79.20 (−106.34–52.05)

87.6%

<0.01

3 studies

Topical+T vs. IV + T

10.90 (−7.95–29.72)

62.5%

0.07

1 study

IV + topical+T vs. IV + topical

106.80 (13.04–200.56)

NA

NA

1 study

IV + topical+T vs. T

−849.80(−987.51–712.09)

NA

NA

Transfusion risk

(PMID:29544472;PMID:29257010;PMID:27267228;PMID:26507526;PMID:27222617;PMID:24816760;PMID:26894222;PMID:24768543;PMID:12697586;PMID:11476309;PMID:10673876)

1 study

IV vs. control

0.23 (0.08–0.74)

NA

NA

1 study

Topical vs. control

0.35 (0.13–1.00)

NA

NA

1 study

Topical vs. IV

1.48 (0.43–5.14)

NA

NA

1 study

IV + topical vs. IV

0.24 (0.03–2.23)

NA

NA

1 study

Oral vs. topical

0.73 (0.16–3.38)

NA

NA

1 study

T VS. IV + topical

20.20 (1.13–360.28)

NA

NA

5 studies

IV + T vs. T

0.09 (0.04–0.17)

0%

0.77

3 studies

Topical+T vs. T

0.19 (0.10–0.37)

46.2%

0.16

3 studies

Topical+T vs. IV + T

0.99 (0.34–2.85)

0%

0.76

1 study

IV + Topical+T vs. T

0.05 (0.00–0.88)

NA

NA

The change of Hb

(PMID:29544472;PMID:29257010;PMID:27267228;PMID:27194493;PMID:26507526;PMID:27259391;PMID:27222617;PMID:26894222;PMID:24768543;PMID:11476309)

1 study

IV vs. control

1.17 (0.54–1.80)

NA

NA

1 study

Topical vs. control

1.42 (0.78–2.06)

NA

NA

1 study

Topical vs. IV

0.25 (−0.32–0.82)

NA

NA

2 studies

IV + topical vs. IV

0.67 (0.48–0.86)

0%

0.81

1 study

Oral vs. topical

0.20 (−0.13–0.53)

NA

NA

1 study

T VS. IV + topical

−1.61 (−1.90–1.32)

NA

NA

3 studies

IV + T vs. T

2.50 (2.09–2.90)

94.8%

<0.01

2 studies

Topical+T vs. T

1.42 (0.84–2.00)

5.4%

0.30

4 studies

Topical+T vs. IV + T

0.57 (0.31–0.84)

92.0%

<0.01

1 study

IV + topical+T vs. IV + topical

−0.20 (−0.38–0.02)

NA

NA

1 study

IV + topical+T vs. T

1.41 (1.11–1.71)

NA

NA

DVT

(PMID:29257010;PMID:27194493;PMID:26507526;PMID:27259391;PMID:24816760;PMID:26894222;PMID:24768543;PMID:12697586;PMID:10673876; PMID:8636182)

1 study

IV + topical vs. IV

0.33 (0.01–8.35)

NA

NA

3 studies

IV + T vs.T

0.80 (0.24–2.63)

0%

0.50

1 study

Topical+T vs. IV + T

0.55 (0.05–6.21)

NA

NA

PE

(PMID:29257010;PMID:27194493;PMID:26507526;PMID:27259391;PMID:24816760;PMID:26894222;PMID:10673876;PMID:8636182)

1 study

IV + topical vs. IV

0.33 (0.01–8.35)

NA

NA

2 studies

IV + T vs. T

0.22 (0.24–2.14)

0%

0.83

1 study

Topical+T vs. IV + T

0.55 (0.05–6.21)

NA

NA

  1. Notes: WMD weighted mean difference, 95%CI 95% confidence intervals, Hb hemoglobin, DVT deep vein thrombosis, PE pulmonary embolism, Control = placebo; IV=IV TXA; topical = topical TXA; IV + topical = IV-combined topical TXA; Oral = oral TXA; T = placebo+tourniquets; IV + T = IV TXA + tourniquets; Topical+T = topical TXA + tourniquets; IV + topical+T = IV-combined topical TXA + tourniquets